BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7525884)

  • 1. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
    Einhorn LH; Roth BJ; Ansari R; Dreicer R; Gonin R; Loehrer PJ
    J Clin Oncol; 1994 Nov; 12(11):2271-6. PubMed ID: 7525884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
    Dreicer R; Propert KJ; Roth BJ; Einhorn LH; Loehrer PJ
    Cancer; 1997 Jan; 79(1):110-4. PubMed ID: 8988734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study.
    Dreicer R; Lallas TA; Joyce JK; Anderson B; Sorosky JI; Buller RE
    Am J Clin Oncol; 1998 Jun; 21(3):287-90. PubMed ID: 9626800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.
    Roth BJ; Dreicer R; Einhorn LH; Neuberg D; Johnson DH; Smith JL; Hudes GR; Schultz SM; Loehrer PJ
    J Clin Oncol; 1994 Nov; 12(11):2264-70. PubMed ID: 7525883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
    J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
    Planting AS; de Wit R; van der Burg ME; Stoter G; Verweij J
    Ann Oncol; 1996 Dec; 7(10):1080-2. PubMed ID: 9037369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
    Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
    J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial.
    Sandler A; Fox S; Meyers T; Christou A; Weber G; Gonin R; Loehrer PJ; Einhorn LH; Dreicer R
    Am J Clin Oncol; 1998 Apr; 21(2):180-4. PubMed ID: 9537208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
    Igawa M; Kadena H; Ueda M; Usui T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S1-4. PubMed ID: 7527732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer.
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Cancer Chemother Pharmacol; 2000; 45(4):279-83. PubMed ID: 10755315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Takahashi S; Suzuki M; Kume H; Matsumoto S; Okamoto N; Nishimatsu H; Tomita K; Kitamura T
    Jpn J Clin Oncol; 2005 Feb; 35(2):79-83. PubMed ID: 15709091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.